These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 3061957)

  • 1. Enkephalinergic mechanisms in the "compensated" phase of Parkinson's disease.
    Sandyk R
    Int J Neurosci; 1988 Oct; 42(3-4):301-3. PubMed ID: 3061957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypothalamic compensatory mechanisms in Parkinson's disease.
    Sandyk R
    Int J Neurosci; 1989 Jan; 44(1-2):135-42. PubMed ID: 2485819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Expression of the enzymes of dopamine synthesis in non-dopaminergic neurons: functional significance and regulation].
    Ugriumov MV
    Usp Fiziol Nauk; 2007; 38(4):3-20. PubMed ID: 18064905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synaptic dysfunction in Parkinson's disease.
    Picconi B; Piccoli G; Calabresi P
    Adv Exp Med Biol; 2012; 970():553-72. PubMed ID: 22351072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tyrosine hydroxylase expression and activity in nigrostriatal dopaminergic neurons of MPTP-treated mice at the presymptomatic and symptomatic stages of parkinsonism.
    Kozina EA; Khakimova GR; Khaindrava VG; Kucheryanu VG; Vorobyeva NE; Krasnov AN; Georgieva SG; Kerkerian-Le Goff L; Ugrumov MV
    J Neurol Sci; 2014 May; 340(1-2):198-207. PubMed ID: 24768159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How compensation breaks down in Parkinson's disease: Insights from modeling of denervated striatum.
    Navntoft CA; Dreyer JK
    Mov Disord; 2016 Mar; 31(3):280-9. PubMed ID: 26890687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurochemical compensation after nigrostriatal bundle injury in an animal model of preclinical parkinsonism.
    Zigmond MJ; Acheson AL; Stachowiak MK; Stricker EM
    Arch Neurol; 1984 Aug; 41(8):856-61. PubMed ID: 6147127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three mechanisms by which striatal denervation causes breakdown of dopamine signaling.
    Dreyer JK
    J Neurosci; 2014 Sep; 34(37):12444-56. PubMed ID: 25209283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Partial dopamine loss enhances activated caspase-3 activity: differential outcomes in striatal projection systems.
    Ariano MA; Grissell AE; Littlejohn FC; Buchanan TM; Elsworth JD; Collier TJ; Steece-Collier K
    J Neurosci Res; 2005 Nov; 82(3):387-96. PubMed ID: 16180225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sprouting of dopamine terminals and altered dopamine release and uptake in Parkinsonian dyskinaesia.
    Lee J; Zhu WM; Stanic D; Finkelstein DI; Horne MH; Henderson J; Lawrence AJ; O'Connor L; Tomas D; Drago J; Horne MK
    Brain; 2008 Jun; 131(Pt 6):1574-87. PubMed ID: 18487277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do compensatory processes underlie the preclinical phase of neurodegenerative disease? Insights from an animal model of parkinsonism.
    Zigmond MJ
    Neurobiol Dis; 1997; 4(3-4):247-53. PubMed ID: 9361301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Synthesis of monoamines by non-monoaminergic neurons: illusion or reality?].
    Ugrumov MV
    J Soc Biol; 2009; 203(1):75-85. PubMed ID: 19358813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modeling of presymptomatic and symptomatic stages of parkinsonism in mice.
    Ugrumov MV; Khaindrava VG; Kozina EA; Kucheryanu VG; Bocharov EV; Kryzhanovsky GN; Kudrin VS; Narkevich VB; Klodt PM; Rayevsky KS; Pronina TS
    Neuroscience; 2011 May; 181():175-88. PubMed ID: 21382448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DA uptake sites, D1 and D2 receptors, D2 and preproenkephalin mRNAs and Fos immunoreactivity in rat striatal subregions after partial dopaminergic degeneration.
    Chritin M; Blanchard V; Raisman-Vozari R; Feuerstein C; Agid Y; Javoy-Agid F; Savasta M
    Eur J Neurosci; 1996 Dec; 8(12):2511-20. PubMed ID: 8996800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transplantation of autologous sympathetic neurons as a potential strategy to restore metabolic functions of the damaged nigrostriatal dopamine nerve terminals in Parkinson's disease.
    Nakao N; Shintani-Mizushima A; Kakishita K; Itakura T
    Brain Res Rev; 2006 Sep; 52(2):244-56. PubMed ID: 16644019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson's disease.
    Boileau I; Guttman M; Rusjan P; Adams JR; Houle S; Tong J; Hornykiewicz O; Furukawa Y; Wilson AA; Kapur S; Kish SJ
    Brain; 2009 May; 132(Pt 5):1366-75. PubMed ID: 19153147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MPTP Mouse Model of Preclinical and Clinical Parkinson's Disease as an Instrument for Translational Medicine.
    Mingazov ER; Khakimova GR; Kozina EA; Medvedev AE; Buneeva OA; Bazyan AS; Ugrumov MV
    Mol Neurobiol; 2018 Apr; 55(4):2991-3006. PubMed ID: 28456940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neostriatal mechanisms in Parkinson's disease.
    Chase TN; Oh JD; Blanchet PJ
    Neurology; 1998 Aug; 51(2 Suppl 2):S30-5. PubMed ID: 9711978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Experimental modeling of functional deficiency of the nigrostriatal dopaminergic system in mice].
    Kozina EA; Khaindrava VG; Kudrin VS; Kucherianu VG; Klodt PD; Bocharov EV; Raevskiĭ KS; Kryzhanovskiĭ GN; Ugriumov MV
    Ross Fiziol Zh Im I M Sechenova; 2010 Mar; 96(3):270-82. PubMed ID: 20535997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CNS compensation to dopamine neuron loss in Parkinson's disease.
    Lloyd KG
    Adv Exp Med Biol; 1977; 90():255-66. PubMed ID: 930746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.